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During schistosomiasis, parasite-derived glycoconjugates play a
key role in manipulation of the host immune response, associated
with persistence of the parasite. Among the candidate host recep-
tors that are triggered by glycoconjugates are C-type lectins (CLRs)
on dendritic cells (DCs), which in concerted action with Toll-like
receptors determine the balance in DCs between induction of
immunity versus tolerance. Here we report that the CLR DC-SIGN
mediates adhesion of DCs to authentic glycolipids derived from
Schistosoma mansoni cercariae and their excretory/secretory prod-
ucts. Structural characterization of the glycolipids, in combination
with solid phase and cellular binding studies revealed that
DC-SIGNbinds to the carbohydratemoieties of both glycosphingo-
lipid species with Gal1–4(Fuc1–3)GlcNAc (LewisX) and Fuc1–
3Gal1–4(Fuc1–3)GlcNAc (pseudo-LewisY) determinants.
Importantly, these data indicate that surveying DCs in the skinmay
encounter schistosome-derived glycolipids immediately after infec-
tion. Recent analysis of crystals of the carbohydrate binding domain
of DC-SIGN bound to LewisX provided insight into the ability of
DC-SIGN to bind fucosylated ligands. Using molecular modeling
we showed that the observed binding of the schistosome-specific
pseudo-LewisY to DC-SIGN is not directly compatible with the
model described. To fit pseudo-LewisY into the model, the orienta-
tion of the side chain of Phe313 in the secondary binding site of
DC-SIGN was slightly changed, which results in a perfect stacking
of Phe313 with the hydrophobic side of the galactose-linked fucose
of pseudo-LewisY. We propose that pathogens such as S. mansoni
may use the observed flexibility in the secondary binding site of
DC-SIGN to target DCs, which may contribute to immune escape.
Schistosomiasis is a human parasitic disease caused by helminths of
the genus Schistosoma that affect more than 200 million people world-
wide (1). One of the most striking features of schistosomiasis is that the
worms are experts in modulation and evasion of the host immune
response, to enable their survival, migration, and development in differ-
ent host tissues. Schistosomes have a complicated life cycle, requiring
both a vertebrate and a snail host. Infection starts when cercariae
released by the snail penetrate the host via the skin and transform into
schistosomula. Schistosomula migrate to the portal system and develop
to mature adult worms that mate and produce eggs. The eggs that
become lodged within host tissues are primarily responsible for the
development of a strong anti-inflammatory Th2 response that enables
parasite survival and induces granuloma formation around the eggs,
which is a major cause of pathology (1).
During infection the immune system is continuously challenged with
an array of molecules associated with parasite metabolism and repro-
duction. However, little is known about the molecular mechanism
behind this challenging of host immune responses, nor which cellular
receptors are involved. Schistosomal glycoconjugates (glycoproteins
and glycolipids) are shown to play important roles in host parasite inter-
actions (2), which may include evasion mechanisms exploited by the
parasites. These glycoconjugates are often developmentally regulated
antigens that are expressed during different life cycle stages. Proteins of
different schistosoma life cycle stages carry bothN- andO-glycans (2, 3).
In addition, schistosomes synthesize highly immunogenic glycosphin-
golipids, especially in the egg and cercarial stage (4, 5). The stage-asso-
ciated synthesis of carbohydrate structures on these glycolipids is par-
alleled by changes in the ceramide structures during the life cycle (6–8).
Schistosome glycosphingolipids have a typical core structure that differs
from that in vertebrates. Remarkably, the glucocerebroside is not galac-
tosylated tomake lactosylceramide as in vertebrates, but is insteadmod-
ified by addition of a GalNAc residue to generate GalNAc1–4Glc1-
ceramide, the so-called “schisto-core” (4). Both protein-linked glycans
and glycosphingolipids contain a variety of terminal glycan epitopes,
many of which are highly fucosylated and include glycan antigens such
as GalNAc1–4GlcNAc (LacdiNac, LDN),2 Fuc1–3GalNAc1–
4GlcNAc (F-LDN), GalNAc1–4(Fuc1–3)GlcNAc (LDN-F),
GalNAc1–4(Fuc1–2Fuc1–3)GlcNAc (LDN-DF), and Gal1–
4(Fuc1–3)GlcNAc (LewisX, LeX) (2, 9–14).
Several findings indicate important roles for LeX antigens in host-
schistosome interactions. LeX antigens have been found in glycoconju-
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gates of all life cycle stages, such as membrane-bound glycoproteins of
adult schistosomes, secreted egg and gut glycoproteins (15), and cer-
carial glycolipids (5). Interestingly, LeX-containing glycoconjugates are
shown to induce proliferation of B-cells from infected animals, which
secrete interleukin-10 (IL-10) and prostaglandin E2 (PGE2), and to
induce the production of IL-10 by peripheral blood mononuclear cells
from schistosome-infected individuals (16, 17). In a murine schisto-
somemodel, LeX is an effective adjuvant for induction of a Th2 response
(18).
Recognition of an invading pathogen by cells of the immune system is
mediated by receptors on antigen-presenting cells. On dendritic cells
(DCs) two receptor families are involved in the recognition of patho-
gens, Toll-like receptors (TLRs) that recognize common pathogen-as-
sociated molecular patterns, and C-type lectins (CLRs) that bind to
glycan antigens (19). DCs express several TLRs, depending on their
developmental stage and lineage (20). Several studies have shown that
bacterial products induce maturation of DCs via TLRs (21–23).
Recently it was shown that the schistosome-specific phosphatidylserine
(PS) activates TLR2 and induces mature DCs to activate IL-10-produc-
ing regulatory T cells (24). DCs also express a variety of CLRs that
recognize glycan antigens in a Ca2-dependent manner using highly
conserved carbohydrate recognition domains (19, 25). Several CLRs
have been implicated to play a role in the recognition of pathogens. An
important question still remaining is whether the principal function of
CLRs is to capture pathogens, or to recognize self-antigens and suppress
immunity (26). Current views are that the balance between triggering
TLRs and CLRs may fine tune the immune response toward immune
activation or tolerance. Recognition of glycans alone by DC lectins may
favor immune suppression, whereas pathogen recognition in a situation
of “danger” (when TLRs are triggered) induces immune activation
(26, 27).
As a first approach to understand the molecular basis of the role of
LeX and other schistosome glycan antigens in interactions with their
host, we set out to investigate the receptors on antigen-presenting
cells that recognize the schistosome glycan antigens. Recently we
showed that the DC-specific C-type lectin DC-SIGN (dendritic cell-
specific ICAM-3 grabbing non-integrin, CD209) binds to Schistoso-
ma mansoni soluble egg antigens (SEA) via LeX, but the actual
ligands within SEA have not yet been identified (28). DC-SIGN is a
human type II transmembrane CLR that contains only one C-termi-
nal CRD and is abundantly expressed on immature DCs (iDCs). DC-
SIGN has affinity for glycoconjugates containingmannose,N-acetyl-
glucosamine and fucose and interacts with many pathogens.
Multivalent binding of its ligands is thought to be achieved by the
formation of tetramers (29, 30). Using site-directed mutagenesis,
molecular modeling, and docking of different Lewis antigens in the
CRD of DC-SIGN we could demonstrate that the amino acid Val351
in DC-SIGN is essential for binding the Fuc1–3/4-GlcNAc moiety
of the Lewis antigens LeX, Lea, Leb, and LeY (28, 31, 32). In this study
we have demonstrated that DC-SIGN strongly binds to authentic
cercarial glycosphingolipids of S. mansoni, but not to egg glycolipids.
Structural characterization of the glycan moieties of the glycosphin-
golipid species revealed that a pentasaccharide containing LeX is one
of the main ligands recognized by DC-SIGN. Unexpectedly, we
found that DC-SIGN also binds to glycosphingolipid species carry-
ing a hexasaccharide terminating with Fuc1–3Gal(1–4)(Fuc1–
3)GlcNAc-R (pseudo-LeY), a glycan antigen that so far only has been
found within schistosomes.
EXPERIMENTAL PROCEDURES
Cells and Antibodies—iDCs were obtained from human peripheral
blood mononuclear cells (PBMCs) by a CD14 magnetic microbeads
isolation (MACS; Miltenyibiotec) (33). The obtained CD14 mono-
cytes were differentiated into iDCs in the presence of IL-4 and granulo-
cyte-macrophage colony-stimulating factor (500 and 800 units/ml,
respectively; Schering-Plough, Belgium). At day 6, the phenotype of the
cultured DCs was confirmed by flow cytometric analysis. The DCs
expressed high levels of major histocompatibility complex class I and II,
CD11b, CD11c, and ICAM-1 and low levels of CD80 and CD86. Stable
transfectants of K562 cells expressing DC-SIGN (34) were kindly pro-
vided by Dr. T. Geijtenbeek. The mAb AZN-D1 is a blocking anti-DC-
SIGN antibody described previously (35). DC-SIGN-Fc consists of the
extracellular portion of DC-SIGN (amino acid residues 64–404) fused
at the C terminus to a human IgG1-Fc fragment into the Sig-pIgG1-Fc
vector (32). The peroxidase-labeled goat anti-human IgG-Fc or goat
anti-mouse IgM were both from Jackson, West Grove, PA. The goat
anti-mouse Alexa Fluor 488 secondary antibody was obtained from
Molecular Probes, Inc., Eugene, OR.
Glycolipid Purification—Lyophilized S. mansoni cercariae and eggs
were kindly provided by Dr. Michael J. Doenhoff (School of Biological
Science, University of Wales, Bangor, UK). S. mansoni excretory/secre-
tory (ES) products were kindly provided by Dr. M. de Jong-Brink
(FALW, VU University, Amsterdam, NL). The cercarial and egg glyco-
lipidswere purified by organic solvent extraction, saponification, desalt-
ing, and anion-exchange chromatography as described previously (5).
Neutral glycolipids were separated by HPLC (latrobeads 6RS-8010, 10
m, 4.6 mm  500 mm; Macherey and Nagel, Du¨ren, Germany) at a
flow rate of 1ml/min using a binary linear gradient from 100% solvent A
(chloroform/methanol/water, 83:16:1, by volume) in 60min to 60% sol-
vent B (chloroform/methanol/water, 10:70:20, by volume) followed by a
20-min elution step with 100% solvent B.
Release andPurification of LeX andPseudo-LeYOligosaccharides from
the Ceramide Moieties—Oligosaccharides were released from cercarial
and ES glycolipids by treatment with recombinant endoglycocerami-
dase II (from Rhodococcus spp., Takara Shuzu Co., Otsu, Shiga, Japan).
Released oligosaccharides were separated from ceramide moieties by
reversed-phase (RP-) chromatography as described previously (5). LeX
and pseudo-LeY glycans were fractionated and separated from remain-
ing glycolipid-derived oligosaccharide species by HPLC on a TSK-Am-
ide 80 column (4mm 250mm;Tosoh, Amsterdam,NL) using a linear
gradient from 100% solvent A (35% acetic acid, buffered with triethyl-
amine to pH 7.3 and 65% acetonitrile) to 100% solvent B (50% acetic
acid, buffered with triethylamine to pH 7.3 and 50% acetonitrile) at a
flow rate of 1 ml/min. Fractions (500 l) were analyzed by MALDI-
TOF-MS and MS/MS.
Neoglycolipid Synthesis—Pure glycolipid-derived oligosaccharide
fractions containing either LeX or pseudo-LeY glycans (80 g each) as
well as lacto-N-fucopentaose III (LNFPIII; 100g; Dextra Laboratories,
Reading, UK) were used for synthesis of neoglycolipids by coupling to
1,2-sn-dipalmitoylphosphatidylethanolamine via reductive amination
(36). Resulting products were analyzed by MALDI-TOF-MS.
Enzyme-linked Immunosorbent Assay (ELISA)—Total egg and cer-
carial glycolipids were diluted in ethanol on NUNC maxisorb plates
(Roskilde, Denmark), and incubated for 60 min at 37 °C to coat the
glycolipids to the plate. Plates were blockedwith 1%ELISA grade bovine
serum albumin (fraction V, fatty acid-free; Calbiochem) and incubated
with DC-SIGN-Fc (3 g/ml) (32). Binding was detected using a perox-
idase-labeled goat antihuman IgG-Fc (Jackson). Separated glycolipid
fractions (8.5 ng) and neoglycolipids were coated on polysorb plates
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(Nunc,Wiesbaden, Germany) and similarly analyzed by ELISA for reac-
tivity withDC-SIGN-Fc (3g/ml) using peroxidase-conjugated antihu-
man IgG (4.6 g/ml; Sigma-Aldrich). EDTA (10 mM, Roth, Karlsruhe,
Germany) was addedwhen indicated to investigate whether the binding
was calcium-dependent.
MALDI-TOF-MS and MS/MS Analysis—MALDI-TOF-MS analysis
was performed on an Ultraflex time-of-flight mass spectrometer
(Bruker-Daltonik, Bremen, Germany) equipped with a nitrogen laser
and a LIFT-MS/MS facility as described previously.3 The instrument
was operated in the positive-ion reflector mode throughout using
6-aza-2-thiothymine (Sigma-Aldrich) as matrix. About 100–500 spec-
tra were summarized in each case.
Cellular Adhesion Assay—96-well plates (NUNC maxisorb) were
coated overnight at room temperature with S. mansoni cercarial and
egg glycolipids, pseudo-LeY neoglycolipid, LeX neoglycolipid, or glo-
botriaosylceramide (Gb3) and blocked with 1% bovine serum albumin.
Cells labeled with Calceine AM (Molecular Probes), were added for
1.5 h at 37 °C in the presence or absence of 20 g/ml mAbs AZN-D1.
Non-adherent cells were removed by gently washing. Adherent cells
were lysed, and fluorescence was quantified on a Fluostar spectrofluo-
rimeter (BMG Labtech, Offenburg, Germany). Results are expressed as
the mean percentage of adhesion of triplicate wells.
Isolation of Schistosoma mansoni Cercarial ES Products—Free cer-
cariae were obtained from S. mansoni parasitized Biomphalaria gla-
brata snails by inducing the shedding process basically as described by
Sluiters et al. (37). The free swimming cercariae obtained were trans-
ferred to 60 ml of water. After 5 h, the cercariae/schistosomula were
removed, and the remaining water containing the ES products was
concentrated.
Molecular Modeling—The coordinates of the crystal structure of
human DC-SIGN interacting with the LeX-containing pentasaccharide
LNFPIII (38) (code 1SL5) were taken from the Protein Data Bank (39).
The structure was edited using Sybyl software (Tripos Inc., St Louis), to
contain only one protein monomer together with calcium ions, the LeX
trisaccharide, and the two water molecules that play an important role
in bridging O4 of galactose to the protein surface. Protein hydrogen
atoms were added, the peptide atoms partial charges were calculated
using the Pullman procedure, and the calcium ions were given a charge
of 2. Atom types and charges for oligosaccharides were defined using
the PIM parameters developed for carbohydrates (40).
Pseudo-LeY was built by adding one fucose on position 3 of the ter-
minal galactose residue. The systematic search procedure of Sybyl was
used to vary the two torsion angles at this glycosidic linkage together
with the two torsion angles of the Phe313 side chain. Only one confor-
mational family was identified. Subsequent energy minimization was
performed using the Tripos force field (41) with geometry optimization
of the sugar and the side chains of amino acids in the binding sites. A
distance-dependent dielectric constant was used in the calculations.
Energyminimizationswere carried out using the Powell procedure until
a gradient deviation of 0.05 kcalmol1Å1 was attained.
RESULTS
Recognition of S. mansoni Cercarial Glycolipids by DC-SIGN—To
investigate their binding to DC-SIGN, authentic glycolipids from
S. mansoni cercariae, and eggs were isolated by organic solvent extrac-
tion (5) and assayed by ELISA using soluble DC-SIGN-Fc. In parallel,
unrelated glycolipids, such as globotriaosylceramide (Gb3), Forssman
antigen (FA), and bovine gangliosides (BG) were tested together with a
synthetic LNFPIII-neoglycolipid to evaluate the binding specificity of
DC-SIGN as well as the potential influence of the structure of the lipid
moiety in this assay. The results revealed that DC-SIGN-Fc strongly
binds cercarial glycosphingolipids and the LNFPIII-neoglycolipid,
whereas a weak binding was observed to egg-derived glycolipids. The
remaining types of glycolipids were not recognized at all (Fig. 1, A and
B). Hence, it can be concluded that recognition by DC-SIGN is medi-
ated by the carbohydrate unit and independent of the lipid part of the
respective molecules.
Characterization and Fractionation of Total Cercarial Glycolipids—
To allow the subsequent analysis of the glycolipid species that bind
DC-SIGN, total cercarial glycolipids were analyzed by MALDI-TOF
3 Geyer, H., Wuhrer, M., Resemann, A., and Geyer, R. (August 31, 2005) J. Biol. Chem.
10.1074/jbc.M5.5985200
FIGURE 1. Binding of DC-SIGN to S. mansoni cercarial glycolipids and LNFPIII-neo-
glycolipid.A, ELISAwasperformed todetermine thebinding reactivity and specificity of
DC-SIGN to egg glycolipids (Egg GL), total cercarial glycolipids (Cerc. GL), Forssman anti-
gen (FA), globotriaosylceramide (Gb3), LNFPIII-neoglycolipid (LNFPIII NGL), and bovine
gangliosides (BG). Similar amounts of glycolipids (3 ng/well) were applied in each case.
Data represent a typical result out of three experiments performed in duplicate. B, titra-
tion of egg glycolipids (Egg GL), total cercarial glycolipids (Cerc. GL), and LNFPIII-neogly-
colipid (LNFPIII NGL) was performed, starting with 10 ng/well, to determine the binding
affinity of DC-SIGN. Results are a typical representative of three independent experi-
ments performed in triplicate.
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MS (Fig. 2). In agreement with previous studies (5), a complex pat-
tern of different glycolipids was registeredmainly because of the high
heterogeneity of the present ceramide moieties. Prevailing species
exhibited monosaccharide compositions of Hex2HexNAc2dHex1,
Hex2HexNAc3dHex1, and Hex2HexNAc2dHex2, thus reflecting cera-
mide pentahexoside and hexahexoside species with the LeX or pseudo-
LeY determinants as described (5). In addition, a number of major
and minor signals was registered which reflected the presence of addi-
tional glycolipids with diverging ceramide and carbohydrate composi-
tions. Based on previous studies on the ceramide composition of
cercarial glycolipids (7) the cluster of ions at m/z 1978.9 can be con-
cluded to comprise species with monosaccharide compositions of
Hex1HexNAc3dHex4 and Hex2HexNAc3dHex3, which is corroborated
by the detection of the respective free oligosaccharides after endoglyco-
ceramidase treatment (TABLE ONE). To obtain individual glycolipid
fractions, cercarial glycolipids were subjected to HPLC separation, and
the isolated fractions were analyzed by ELISA for their capacity to bind
DC-SIGN (Fig. 3A). The results revealed that DC-SIGN mainly recog-
nized glycolipids that occurred in HPLC fractions 40–50, whereas spe-
cies with elongated carbohydrate units did not react. Subsequent anal-
ysis of fractions 40–50 by MALDI-TOF-MS demonstrated that each
fraction comprised a mixture of glycolipids carrying LeX or pseudo-LeY
moieties (Fig. 3, B–E). Because of the observed ceramide heterogeneity,
a clear separation into fractions containing solely LeX or pseudo-LeY
determinants was not possible. To determine which of these glycan
moieties are recognized by DC-SIGN, we decided to synthesize neogly-
colipids, using purified carbohydrate moieties that were released from
the cercarial glycosphingolipids.
Purification of the GlycanMoieties of Cercarial Glycolipids—Glycans
were released from total cercarial glycolipids by endoglycoceramidase
treatment, separated from remaining (glyco)lipids by reversed-phase
chromatography and analyzed by MALDI-TOF-MS (Fig. 4). In agree-
ment with the spectrum obtained in the case of total cercarial glycolip-
ids (Fig. 2), the results confirmed the preponderant occurrence of oli-
gosaccharides with monosaccharide compositions consistent with the
presence of a LeX or a pseudo-LeY determinant. In addition, several
minor oligosaccharides with divergent compositions have been regis-
tered (TABLEONE). To obtain individual glycan species, the total mix-
ture of oligosaccharides was subjected toHPLC separation using a TSK-
amide column. Collected fractions were screened byMALDI-TOF-MS.
Fractions containing the LeX pentasaccharide (m/z 917.3 [M  Na])
plus additional pseudo-LeY (m/z 1063.6 [M Na]) and/or LeX hexa-
saccharide species (m/z 1120.3 [MNa]) were reapplied to HPLC, to
reduce peak heterogeneity and to obtain pure compounds asmonitored
by MALDI-TOF-MS (see insets in Fig. 5, A and B).
Characterization of LeX and Pseudo-LeY Glycans by MALDI-
TOF-MS/MS—The identity of the isolated glycans was established by
tandemmass spectrometry.MS/MS analysis verified that the parent ion
with the mass of m/z 917.3 [M  Na] consisted of a pentasaccharide
with a composition of Hex2HexNAc2dHex1 (Fig. 5A). In addition to the
sequential release of the five monosaccharide units, two characteristic
fragment ions, B2 and C2 atm/z 534.2 andm/z 552.2, could be observed
in agreement with the presence of a LeX trisaccharide unit. The linkage
of fucose to the subterminal HexNAc residue is confirmed by a Y3
fragment ion atm/z 755.5. By the same line of evidence, the glycan with
the mass ofm/z 1063.3 [MNa] (inset in Fig. 5B) could be shown to
comprise a dHex-Hex-(dHex-)HexNAc unit because of the observed B3
and C3 fragment ions atm/z 680.1 andm/z 698.1, respectively (Fig. 5B).
Hence, the obtained MS/MS spectra displayed all diagnostically rele-
vant fragment ions to be expected for the cercarial glycolipid-derived
LeX pentasaccharide and pseudo-LeY hexasaccharide units described
previously (5). Furthermore, mass spectrometry revealed a high purity
of the LeX and pseudo-LeY glycan fractions obtained.
Binding of DC-SIGN to LeX and Pseudo-LeY Neoglycolipids—Purified
LeX and pseudo-LeY glycans were converted into neoglycolipids by cou-
pling to 1,2-sn-dipalmitoylphosphatidyl-ethanolamine (DPPE) via
reductive amination. Resulting products were analyzed by MALDI-
TOF-MS (Fig. 6). LeX neoglycolipid led to a signal ofm/z 1615.0 [M-H
2Na] (Fig. 6A) in agreement with the calculated mass of the LeX pen-
tasaccharide (m/z 917.3) and the mass increment of DPPE (m/z 692),
taking into consideration that one oxygen is lost during reductive ami-
nation and the acidic proton of DPPE is replaced by a sodium ion.
Likewise, pseudo-LeY neoglycolipid was registered with masses of m/z
1739.4 [M  Na] and m/z 1761.1 [M-H  2Na] (Fig. 6B). Both
neoglycolipid samples were quantified by compositional analysis with
regard to their carbohydrate content to ensure the application of
defined amounts of neoglycolipids in subsequent experiments. The
binding of DC-SIGN-Fc to LeX and pseudo-LeY neoglycolipids was
studied by ELISA (Fig. 7). The results revealed an almost equivalent
recognition of the two neoglycolipids by DC-SIGN-Fc when compared
with the LNFPIII-neoglycolipid used as a positive control. This finding
is remarkable as the pseudo-LeY epitope represents, in contrast to LeX,
a parasite-specific carbohydrate structure. To establish whether natural
cell surface-expressed DC-SIGN binds authentic cercarial glycolipids
and neoglycolipids, we performed a cellular adhesion assay. K562 cells
stably transfected with DC-SIGN express high levels of DC-SIGN on
their cell surface as was determined by flow cytometry (Fig. 8A). Cer-
carial glycolipids as well as neoglycolipids containing pseudo-LeY or LeX
FIGURE2.MALDI-TOF-MSanalysisof isolatedglycolipids fromS. mansoni cercariae.
Deduced monosaccharide compositions are assigned to major pseudomolecular ions
([MNa]) comprising LeX (H2N2F1 atm/z 1593.7 or H2N3F1 atm/z 1796.8) and pseudo-
LeY epitopes (H2N2F2 at m/z 1739.8). The cluster of ions culminating in a signal at m/z
1978.9 reflects glycolipids with divergent ceramide and carbohydrate moieties includ-
ing species with monosaccharide compositions of H1N3F4 and H2N3F3. The complex
patternof registered signals is causedby ceramideheterogeneity.H, hexose;N,N-acetyl-
hexosamine; F, deoxyhexose (fucose); Cer, ceramide.
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showed binding to K562 transfected with DC-SIGN, but not to the
parental K562 cell line. There was no binding of cellular DC-SIGN to
egg glycolipids and Gb3. The binding could be blocked by AZN-D1, a
DC-SIGN blocking antibody, and EGTA (Fig. 8B). Human iDCs natu-
rally express DC-SIGN on their cell surface (Fig. 8A). Cercarial glyco-
lipids and the neoglycolipids containing LeX or pseudo-LeY are bound
by DC-SIGN on iDCs (Fig. 8C). Despite the fact that iDCs express mul-
tiple CLRs on their cell surface, adhesion is completely inhibited by the
Ca2-chelator EGTA or a DC-SIGN blocking antibody (Fig. 8C), indi-
cating that binding of the cells to the glycolipids ismediated via theCRD
of DC-SIGN. Hence, these studies demonstrate that DC-SIGN medi-
ates the binding of iDCs to authentic carbohydrate structures uniquely
expressed by S. mansoni cercarial glycolipids.
Docking of Pseudo-LeY Oligosaccharide into DC-SIGN—The docking
of pseudo-LeY in the DC-SIGN binding site was based on the crystal
structure of theDC-SIGNcomplexedwith LeX-containing oligosaccha-
ride (38). Inclusion of hydrogen atoms (not located by x-ray diffraction)
and optimization of the binding site of the DC-SIGN/LeX complex did
not yield any significant change compared with the crystal structure. It
allows us to propose the hydrogen bond network displayed in Fig. 9A,
with involvement of two water molecules that bridge the galactose res-
idue to Ser360 and Glu358 side chains.
TABLE ONE
Compilation of total glycans obtained from glycosphingolipids of S. mansoni cercariae and ES products by endoglycoceramidase treatment
Compositions are assigned in terms of hexose (H),N-acetylhexosamine (N), and deoxyhexose (fucose; F). Relative occurrence of individual compositional species
is roughly estimated from the respective signal intensities registered by MALDI-TOF-MS. Oligosaccharides representing LeX-pentasaccharides, LeX-hexasac-
charides or pseudo-LeY-hexasaccharides are marked in bold type.
Calculated mass [MNa] Observed mass [MNa] Composition Obtained froma
m/z m/z
Glycolipids E/S-products
917.32 917.3 H2N2F1  
933.32 933.2 H3N2  —
958.35 958.2 H1N3F1  
1063.38 1063.6 H2N2F2  
1079.2 1079.2 H3N2F1  —
1104.41 1104.2 H1N3F2  
1120.41 1120.3 H2N3F1  
1136.39 1136.2 H3N3  —
1161.43 1161.3 H1N4F1  —
1241.43 1241.6 H4N2F1 — 
1250.46 1250.3 H1N3F3  —
1266.46 1266.3 H2N3F2  
1282.45 1282.3 H3N3F1  —
1307.46 1307.3 H1N4F2  
1323.48 1323.3 H2N4F1  —
1396.52 1396.3 H1N3F4  
1412.51 1412.3 H2N3F3  —
1428.51 1428.3 H3N3F2  —
1453.55 1453.3 H1N4F3  
1469.54 1469.3 H2N4F2  —
1485.54 1485.3 H3N4F1  —
1510.57 1511.0 H1N5F2 — 
1599.6 1599.4 H1N4F4  
1615.59 1615.4 H2N4F3  —
1631.59 1631.4 H3N4F2  —
1656.62 1656.4 H1N5F3  
1672.62 1672.4 H2N5F2  —
1713.65 1714.3 H1N6F2 — 
1745.66 1745.4 H1N4F5  —
1802.68 1803.4 H1N5F4 — 
1818.68 1818.4 H2N5F3  —
1834.67 1835.4 H3N5F2  —
1859.70 1860.4 H1N6F3 — 
2005.76 2006.4 H1N6F4 — 
2062.78 2063.4 H1N7F3 — 
2151.82 2152.4 H1N6F5 — 
2208.84 2210.4 H1N7F4 — 
2354.89 2355.4 H1N7F5 — 
2500.95 2502.3 H1N7F6 — 
a Relative amounts were estimated as follows:, 0–2.2104;, 2.21–4.6104;, 4.61–6.6104 intensity counts. —, signal not detected.
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Pseudo-LeY was built from this complex by adding a fucose in posi-
tion 3 of the galactose. All possible conformations were tested but all of
them resulted in a steric conflict with the side chain of Phe313. After a
systematic search involving both Phe313 side chain and the fucose ori-
entation, one possiblemode of interaction was identified. The proposed
docking mode is represented in Fig. 9B. The Phe313 side chain would
adopt an orientation different from the one observed in the crystal
structure of DC-SIGN complexed with LeX. The new orientation allows
for a strong “stacking” of the aromatic ring of Phe313 with the most
hydrophobic face of fucose. Such interaction between sugar and
planar side chains are commonly observed in protein-carbohydrate
interactions.
The reorientation of the Phe313 side chain does not cost significant
energy. This side chain adopts a different orientation when compared
with DC-SIGN complexed with LeX or with mannose oligosaccharide
(30, 38). Furthermore, a recent crystallographic work demonstrated a
large conformational change in an arginine residue side chain for stack-
ing to a sugar derivative in a galectin structure (42).
S. mansoni ES Products Comprise Glycolipids with LeX and Pseudo-
LeY Epitopes—It remains to be investigated whether the cercarial glyco-
sphingolipids that have been shown to bind to DC-SIGN in vitro are in
a position that allows an interaction with DCs in vivo as well. However,
DCs are expected to encounter ES products, a mixture of glycoproteins
and glycolipids that is secreted when the cercariae transform to schis-
FIGURE 3. Binding of DC-SIGN to fractionated
glycolipids of S. mansoni cercariae. Binding of
DC-SIGN to S. mansoni cercarial glycolipids was
determinedbyELISAusing solubleDC-SIGN-Fc (A).
Recognized species occurring in fractions 40–50
are dominated by glycolipids carrying LeX and
pseudo-LeY epitopes as confirmedbyMALDI-TOF-
MS. B–E, MALDI-TOF-MS analysis of HPLC-fractions
40, 42, 47, and 51, respectively. Major pseudomo-
lecular ions ([MNa]) comprising LeX-pentasac-
charide (*), pseudo-LeY-hexasaccharide (), and
pseudo-LeY-octasaccharide () units are
marked.
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FIGURE 5.MALDI-TOF-MS and MS/MS analysis of purified glycans with LeX or pseudo-LeY units. A, MALDI-TOF-MS/MS spectrum of the LeX pentasaccharide (m/z 917.3 [M
Na]). Characteristic LeX trisaccharide fragment ions (B2 and C2) and the diagnostically relevant Y3 fragment are marked by asterisks (*). B, MALDI-TOF-MS/MS spectrum of the
pseudo-LeY hexasaccharide (m/z 1063.6 [MNa]). Characteristic pseudo-LeY tetrasaccharide fragment ions (B3 and C3) are again marked by asterisks (*). The signal atm/z 764.2 is
assumed toarise fromring fragmentationaccompaniedby the lossof twowatermolecules (0,2A4-2H2O). Insets, correspondingMS
1 spectra. Assignmentof fragment ions isperformed
according to Domon and Costello (54).
FIGURE 4.MALDI-TOF-MSanalysis of releasedoligosaccharides.Oligosaccharideswere released fromcercarial glycolipids by treatmentwith endoglycoceramidase and analyzed
by MALDI-TOF-MS. Monoisotopic masses of pseudomolecular ions ([M Na]) and deduced monosaccharide compositions are assigned. Signals representing free LeX pentasac-
charide (m/z 917.3), LeX hexasaccharide (m/z 1120.3) as well as pseudo-LeY hexasaccharide (m/z 1063.6) are marked in bold type. H, hexose; N, N-acetylhexosamine; F, deoxyhexose
(fucose).
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tosomula. To determine whether the LeX and pseudo-LeY containing
glycosphingolipids are found within ES products, glycolipids were iso-
lated from ES products collected in vitro from freshly transformed cer-
cariae. Following treatment with endoglycoceramidase the released oli-
gosaccharides were analyzed byMALDI-TOF-MS. The results revealed
that ES product-derived glycolipids comprise species with LeX and
pseudo-LeY determinants together with a wide panel of extended oligo-
fucosylated glycan species, many of which were also recovered in the
cercarial glycolipid fractions (TABLE ONE).
DISCUSSION
In this study the interaction of DC-SIGN with S. mansoni glycolipids
was investigated. In contrast to glycosphingolipids derived from eggs,
glycosphingolipids of S. mansoni cercariae are bound by both recombi-
nant and dendritic cell expressedDC-SIGN. Structural characterization
of the glycolipids revealed that DC-SIGN binds two dominant cercarial
glycosphingolipids, being LeX-containing species and pseudo-LeY spe-
cies (5). In contrast to LeX that is found in both mammals and several
pathogens, pseudo-LeY is an oligosaccharide determinant that may be
unique for schistosomes (5). These are the first natural ligands identified
for DC-SIGN in schistosomes, enabling follow-up studies to elucidate
the function of the interaction between DC-SIGN and schistosome gly-
colipids in host immunity. The observation that egg glycolipids inter-
acted poorly with DC-SIGN is in agreement with previous studies
demonstrating that species with pseudo-LeY determinants are pre-
dominantly found in cercarial glycosphingolipids, whereas LeX contain-
ing glycosphingolipids represent only a very small fraction of total egg
stage glycosphingolipids (5).
Recently more insight was obtained into the ability of DC-SIGN to
bind fucosylated ligands (31, 38). Analysis of crystals of the CRD of
DC-SIGN bound to lacto-N-fucopentaose III (that comprises the LeX
trisaccharide) showed that the 3- and 4-OH groups of the 1–3-linked
fucose form coordination bonds with Ca2 in the primary binding site.
In this position the fucose is close to Val351, which forms tight van der
Waals contacts with the 2-OH group, whereas the terminal galactose
residue contacts the protein via Phe313 in a secondary binding site. From
the proposed models it appears that Val351 in DC-SIGN is close to the
fucose binding site andmakes a strong hydrophobic contact with CH at
position 1 and 2 of fucose (38). By molecular modeling, in combination
with binding studies of cell-surface expressed recombinant wild-type
andmutant forms ofDC-SIGNand its homologue L-SIGN (liver/lymph
node-specific ICAM-3 grabbing nonintegrin), we found very similar
results for the binding mode of LeX in DC-SIGN (31). Both models
predict that a substituent on the 3-OH group of galactose would give a
steric conflict with the side chain of Phe313, which is line with the results
of binding studies that showed that 3-sialylation or sulfation of LeX
abrogates binding (43). However, in the studies described here, we
observed binding of soluble DC-SIGN-Fc, as well as cellular expressed
DC-SIGN, to pseudo-LeY that does carry a fucose 1–3-linked to galac-
tose (5). To fit a fucose on position 3 of galactose into the model, it
appeared necessary to slightly change the orientation of the side chain of
Phe313, a movement that does not cost significant energy. Furthermore,
in this dockingmode a perfect stacking with the hydrophobic side of the
galactose-linked fucose is created.We propose that the secondary bind-
ing site of DC-SIGN is flexible due to the capacity of the side chain of
Phe313 to change orientation, and that pathogens such as S. mansoni
may use this property to target DC-SIGN. Recently, a similar change in
FIGURE 6.MALDI-TOF-MS analysis of neoglycolipids containing LeX or pseudo-LeY epitopes. A and B, MALDI-TOF-MS spectra of LeX (m/z 1615.0 [M-H 2Na]) and pseudo-LeY
(m/z 1739.4 [M Na] and 1761.1 [M-H 2Na]) neoglycolipids, respectively.
FIGURE 7. DC-SIGN-Fc binds to LeX and pseudo-LeY neoglycolipids. Binding of DC-
SIGN-Fc to schistosomal neoglycolipids was tested in ELISA. 10 ng of lacto-N-fucopen-
taose III neoglycolipid (LNFP III) was coated as positive control. In parallel, 8 ng of LeX
neoglycolipid (LeX) and 8 ng of pseudo-LeY neoglycolipid (pseudo-LeY) were applied to
eachwell. Binding of DC-SIGN-Fc to all neoglycolipidswas completely inhibited by addi-
tion of EDTA (Control, only one example shown). Indicated S.D. are based on nine inde-
pendent determinations.
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orientation has been demonstrated for the side chain of Arg144 in the
CRD of galectin-3 upon ligand binding (42). The high resolution x-ray
crystal structures of the CRD of human galectin-3 were solved in com-
plex with N-acetyllactosamine (LacNAc) and a high affinity inhibitor.
The structures showed that the side chain of Arg144 stacks against the
aromatic moiety of the inhibitor, which was possible by a reorientation
of the side chain relative to that seen in the complex with LacNAc.
Antigen-presenting cells, such as DCs and macrophages are the first
immune cells that encounter invading pathogens and are crucially
involved in the initiation and control of innate and adaptive immune
responses (44). They often recognize pathogens through a wide array of
molecules such as (glyco)lipids and acylated proteins or peptides. Inter-
estingly, several studies indicate that glycolipids are capable tomodulate
the human immune system (45–47). The presence of lipid moieties
within pathogen-derived products is essential for activation of specific
pattern recognition receptors, in particular TLR2 (48). It was recently
shown that schistosomal egg glycolipids induce production of pro- and
anti-inflammatory cytokines in monocytes (24). By fractionating and
purification of the lipids, the authors showed thatmono-acetylated lyso-
phosphatidylserine (lyso-PS) promotes the development of T regulatory
cells via interaction with TLR2 on DCs. By contrast, di-acetylated phos-
phatidylserine promotes maturation of DC into a phenotype, termed
DC2, which induces the development of Th2 responses (24).
Herewe report thatDCs interact with authentic cercarial glycosphin-
golipids comprising LeX and pseudo-LeY via the CLR DC-SIGN. This
indicates that DCs may likely interact with schistosomes early in infec-
tion. Schistosomes enter the human host in the cercarial stage, and
these cercariae transform into schistosomula directly after penetration
of the skin by shedding their glycocalyx and secretion of ES products.
Analysis of the glycolipids derived from ES products showed that they
comprise species with LeX and pseudo-LeY determinants. These ES
products that enter the surrounding tissue are good candidate antigens
to be encountered by surveying DCs, such as the DC-SIGN positive
CD1a negative dermal DCs, which are foundmostly in the upper dermis
(35, 49, 50).
A remarkable finding is that human DCs recognize LeX and LDN-F
glycan antigens within schistosomes (28), which can be considered as
“self-glycan” antigens since they are also found on human glycoconju-
gates. It has been proposed that DC-SIGN, which also interacts with
several “self-ligands” such as ICAM-2 and ICAM-3, may principally
function in normal homeostasis, rather than being a true pattern recog-
nition receptor (26). Current views are that pathogens target DC-SIGN
FIGURE 8. DC-SIGN on human dendritic cells
interacts with authentic S. mansoni cercarial
glycolipids and LeX and pseudo-LeY neoglyco-
lipids.TheexpressionofDC-SIGNon transfectants
and iDCs was determined by flow cytometry (A).
Binding of DC-SIGN expressed on K562 transfec-
tants (B) or iDCs (C) to glycolipids (GL) and neogly-
colipids (NGL) was determined by plate adhesion
assay in the presence or absence of EGTA, or a
blocking mAb to DC-SIGN (AZN-D1). All results are
representative of three independent experiments,
performed in triplicate.
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or other CLRs to promote immune escape (51). For example,Mycobac-
terium tuberculosis secretes glycoconjugates that are recognized byDC-
SIGN to down-regulate TLR-induced immune activation (52). Patho-
gens likeHIV-1 havemany strategies to evade immune recognition or to
modulate immune responses to survive in their hosts. In HIV-1 infec-
tion, DC-SIGN plays a role in internalization of the virus into DCs, but
instead of being routed to the lysosomal compartment for degradation,
part of the infectious virus remains hidden in the DC, to subsequently
infect target cells (51). Schistosomes survive for many years in the host
despite a pronounced immune response, indicating that these hel-
minths have effective strategies to escape or suppress the host immune
system. In amousemodel system, SEA and its major glycan antigen LeX
can induce a Th2-mediated immune response, which is associated with
persistence of the pathogen (53). Our data here show that DC-SIGN
does not only recognize the self-glycan ligand LeX within cercarial gly-
colipids, but also glycolipids carrying pseudo-LeY, a non-self structure
that so far is only found within schistosome cercarial glycolipids (5) and
ES products (this study). Pseudo-LeY may be regarded as a glycan anti-
gen that mimics a self-glycan to fit within the CRD of DC-SIGN. The
abundant expression of such self-glycans or glycan antigens that mimic
self-glycans, may allow schistosomes to mislead the host immune sys-
tem by down-regulatingDC function in all stages of infection. However,
DC-SIGN has been shown to internalize schistosome glycoconjugates3
and could also play a role in processing of these glycoconjugates and
antigen presentation. Because currently more than 200 million people
have schistosomiasis, it is challenging to understand the central role of
DCs in both the strong immune response that is evoked upon infection,
as well as in the immune evasion and suppression mechanisms that are
exploited by the schistosomes.
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